Colleen Nawrocki
Family · Willoughby, OHNPI 1437236460
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 429 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,198 and has fallen 98.9% since, to $25 in 2024. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $13.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$882
- Lilly USA, LLC$737
- AstraZeneca$544
- Pfizer$260
- Abbott$199
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,688100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $1,350 |
| Novo Nordisk | 84 | $882 |
| Lilly USA, LLC | 69 | $737 |
| AstraZeneca | 28 | $544 |
| Pfizer | 17 | $260 |
| Abbott | 10 | $199 |
| Boehringer Ingelheim | 17 | $188 |
| Amgen | 11 | $176 |
| GSK | 12 | $173 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $150 |
| Novartis | 8 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $123 |
| Amarin Pharma, Inc. | 3 | $73 |
| Merck | 5 | $69 |
| Nevro Corp. | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Johnson & Johnson | 4 | $53 |
| Radius Health, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
How this compares
$5,688 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 52 | $476 |
| Levothyroxine Sodium | 37 | $398 |
| Gabapentin | 20 | $365 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $312 |
| Rosuvastatin Calcium | 28 | $292 |
| Omeprazole | 26 | $285 |
| Losartan Potassium | 21 | $279 |
| Lisinopril | 35 | $218 |
| Allopurinol | 17 | $217 |
| Metformin Hcl ErMetformin Hcl | 14 | $195 |
| Potassium Chloride | 11 | $177 |
| Simvastatin | 15 | $174 |
| Pantoprazole Sodium | 12 | $161 |
| Amlodipine Besylate | 34 | $146 |
| Metformin Hcl | 25 | $140 |
Paid to pharmacies, not to this prescriber.
Other family in Willoughby
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.